Adalimumab biosimilar (Laboratorios Richmond)

阿达木单抗生物类似药 (Laboratorios Richmond)

Report date: 2024/03/18 16:42:40

Base Information

Drug NameAdalimumab biosimilar (Laboratorios Richmond)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryArgentina
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesLaboratorios Richmond
China Registration ClassN/A

Develop Information

Active CompaniesLaboratorios Richmond S.A.C.I.F.Fp Clinical Pharma SrlCustom Biologics
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A